


c-Kit-IN-5-1

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-18302 | | |
| CAS No.: | 1003311-62-3 | | |
| Molecular Formula: | C ₂₃ H ₁₇ N ₅ O ₂ | | |
| Molecular Weight: | 395.41 | | |
| Target: | c-Kit | | |
| Pathway: | Protein Tyrosine Kinase/RTK | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

| | | | | |
|---|---|--------------------------|------------|------------|
| In Vitro | DMSO : 25 mg/mL (63.23 mM); ultrasonic and warming and heat to 80°C | | | |
| | | Solvent Concentration | Mass | |
| | | | 1 mg | 5 mg |
| | | | 10 mg | |
| Preparing Stock Solutions | 1 mM | 2.5290 mL | 12.6451 mL | 25.2902 mL |
| | 5 mM | 0.5058 mL | 2.5290 mL | 5.0580 mL |
| | 10 mM | 0.2529 mL | 1.2645 mL | 2.5290 mL |
| Please refer to the solubility information to select the appropriate solvent. | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 1.67 mg/mL (4.22 mM); Suspended solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1.67 mg/mL (4.22 mM); Suspended solution; Need ultrasonic | | | |

BIOLOGICAL ACTIVITY

| | |
|--------------------|---|
| Description | c-Kit-IN-5 is potent inhibitor of c-Kit, with IC ₅₀ s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties ^[1] . |
| In Vitro | c-Kit-IN-5 (compound 25) shows more than 200-fold selectivity against KDR, p38, Lck, and Src (IC ₅₀ =>5.0, 40, 7.8, and >5.0 μM, respectively) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | c-Kit-IN-5 (compound 25) (1 mg/kg; i.v.) exhibits CL (0.46 L/h/kg) and V _{dss} (1.59 L/kg) in rats ^[1] . c-Kit-IN-5 (10 mg/kg; p.o.) exhibits AUC _{0-t} (9860 ng•h/mL) C _{max} (1230 ng/mL), T _{1/2} (2.6 h), and F (39%) in rats ^[1] . |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hu E, et, al. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit. J Med Chem. 2008 Jun 12;51(11):3065-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA